Duffy and Kidd Genotyping Facilitates Pretransfusion Testing in Patients Undergoing Long-Term Transfusion Therapy

Diana Remeikiene1, Rasa Ugenskiene2, Arturas Inciura3, Aiste Savukaityte2, Danguole Raulinaityte2, Erika Skrodeniene4, Renata Simoliuniene5, Elona Juozaityte3

1Lithuanian University of Health Sciences, Institute of Oncology, Department of Haematology, Kaunas, Lithuania
2Lithuanian University of Health Sciences, Institute of Oncology, Oncology Research Laboratory, Kaunas, Lithuania
3Lithuanian University of Health Sciences, Institute of Oncology, Department of Oncology, Kaunas, Lithuania
4Lithuanian University of Health Sciences, Department of Laboratory Medicine, Kaunas, Lithuania
5Lithuanian University of Health Sciences, Department of Physics, Mathematics, and Biophysics, Kaunas, Lithuania

Abstract:

Objective: Conventional serologic typing of red blood cell systems other than ABO and RhD can be inaccurate and difficult to interpret in patients who have recently undergone blood transfusion. While molecular-based assays are not used routinely, the usefulness of genotyping was investigated in order to determine patients who may benefit from this procedure.

Materials and Methods: Blood samples were taken from 101 patients with haemato-oncological, chronic renal, or gastroenterological diseases and from 50 donor controls; the samples were tested for Fya and Fyb by applying serologic and genetic methods. All patients had received 3 or more units of RBCs during the last 3 months. An average of 6.1 RBC units were transfused per patient. The average length of time from transfusion until blood sampling was 24.4 days. The haemagglutination test was applied for serological analysis, and the restriction length polymorphism assay was used for genotyping.

Results: In total, 33 (32.7%) patients showed positive reactions with anti-Fya or anti-Fyb while being negative genetically. False-positive Fya results were found in 23 samples, and false-positive Fyb in 10 specimens. During the last 3 months, significantly more RBC units were transfused to patients with discrepant results than to those with accurate phenotyping/genotyping results: median of 5 (mean ± SE: 6.85±0.69) versus median of 4 (mean: 5.71±0.51), respectively (p=0.025). The median length of time after the last transfusion was 25 days (mean: 28.72±2.23 days) in the group with accurate phenotyping/genotyping results versus a median of 14 days (mean: 15.52±1.95 days) in the group with discrepant results (p=0.001). Phenotypes and genotypes coincided in all donor samples.

Conclusion: Genotyping assays for the Duffy system should be considered if the patient underwent blood transfusion less than 3 or 4 weeks before the sample collection. If the time frame from RBC transfusion exceeds 6 weeks, Duffy phenotyping can provide accurate results.

Key Words: Duffy phenotyping, Kidd phenotyping, Genotyping, Multitransfused patients

Address for Correspondence: Diana REMEIKENE, M.D., Lithuanian University of Health Sciences, Institute of Oncology, Department of Haematology, Kaunas, Lithuania
Phone: +370 37326303 E-mail: diana.remeikiene@kaunoklinikos.lt
Received/Geliş tarihi : February 28, 2013
Accepted/Kabul tarihi : November 1, 2013
Introduction

Patients who require multiple transfusions of red blood cells (RBCs), such as those with sickle cell disease (SCD) or β-thalassaemia, have a higher potential risk of alloimmunisation and delayed haemolytic transfusion reactions (DHTRs). The widely described risk of developing antibodies, mostly to Rh, Kell, Duffy, Kidd, and MNS systems, ranges from 18% to 47% [1,2]. Programs to prevent alloimmunisation have been implemented in the centres treating patients with SCD and β-thalassaemia [1,3,4]. In addition to ABO and RhD matching, protocols range from providing limited antigen-matched RBCs for Rh and Kell to extended antigen-matched RBCs for Rh, Kell, Duffy, Kidd, and MNS systems prior to transfusion.

Accurate phenotyping of multitransfused patients is often complicated, mostly due to the presence of circulating transfused donor RBCs in the recipient's blood, leading to discrepancies in the assessment of tests results. The importance of the genotyping of clinically relevant antigens (such as C, c, E, K, Fy^a, Fy^b, Jk^a, Jk^b, and S) in addition to phenotyping is still being discussed for patients with SCD, β-thalassaemia, and other haemoglobinopathies.

However, there is a lack of information about the need for molecular testing for other groups of patients who depend on long-term RBCs transfusions, such as those with myelodysplastic syndrome, myelofibrosis, or chronic renal failure [5,6,7]. Delayed haemolytic transfusion reactions are often an issue in these patients, affecting their quality of life and sometimes being fatal. The selection of antigen-negative RBCs in order to reduce alloimmunisation is often required for patients with long-term transfusions and for those with formed alloantibodies.

The most common causes of DHTR include antibodies against Rh, Kell, Kidd, Duffy, and MNS systems [3,8,9,10]. Serological testing and evaluation of the antigens and antibodies of the Duffy and Kidd systems are among the main problems in multitransfused patients. The correlation between serological and molecular typing of Duffy and Kidd systems demonstrates the benefits of genotyping in patients who depend on chronic RBC transfusions.

The aim of our study was to estimate the value of DNA-based typing of Duffy and Kidd systems for transfused patients. The inclusion criteria were the time frame from the last RBC transfusion being shorter than 8 weeks and the need for further
transfusions. None of the patients were tested for Fy\textsuperscript{a}, Fy\textsuperscript{b}, Jk\textsuperscript{a}, or Jk\textsuperscript{b} antigens before transfusions.

Most of the RBC units received by the haematology patients and some of those received by the oncology patients were leucodepleted, while others were non-leucodepleted. Thus, 62 patients (61.4%) were transfused with leucoreduced RBCs, and 39 (38.6%) with entirely (or by more than half) non-leucoreduced RBCs. The median number of transfusion events per patient was 3 (mean: 3.33±0.21, range: 1-12). A median of 2 (mean: 1.85±0.04, range: 1-4) RBC units were administered per transfusion event and 4 (mean: 6.1±0.41, range: 3-24) units per patient.

**Donors**

In total, 49 blood donors served as controls in our study. Blood samples of donors were obtained by taking 1 or 2 segments of tubes from RBC bags used for transfusions. This control group and the patient group were used to determine frequencies of Duffy and Kidd phenotypes in a Lithuanian population.

Blood samples of all patients and donors were tested for Fy\textsuperscript{a}, Fy\textsuperscript{b}, Jk\textsuperscript{a}, and Jk\textsuperscript{b} antigens by applying serological and molecular methods. Approval for the study was obtained from the Regional Bioethics Committee.

**Serotyping**

Peripheral blood samples were used for Duffy and Kidd phenotyping. Fy\textsuperscript{a}, Fy\textsuperscript{b}, Jk\textsuperscript{a}, and Jk\textsuperscript{b} antigens were determined by haemagglutination using anti-Fy\textsuperscript{a}, anti-Fy\textsuperscript{b}, anti-Jk\textsuperscript{a}, and anti-Jk\textsuperscript{b} Coombs reactive (polyclonal, human) reagents (Antitoxin GmbH, Germany) and DG Gel Coombs cards (Diagnostic Grifols, S.A., Spain). Each microtube of the card contained polymerised dextran in a buffered medium containing preservatives and low ionic strength solution, and was mixed with polyspecific anti-human globulin. The tests were performed according to the manufacturer’s recommendations. The results of the agglutination were expressed by using plus/minus values. Positive results were evaluated from 1+ to +++.  

| Genotype      | Phenotype | Combination of FY alleles | Combination of JK alleles |
|---------------|-----------|---------------------------|---------------------------|
| FY\textsuperscript{a}/FY\textsuperscript{a}  | 7         | Fy(a+b-)                  | JK\textsuperscript{a}/JK\textsuperscript{a}  |
| FY\textsuperscript{a}/FY\textsuperscript{b} | 0         | Fy(a+b+)                  | JK\textsuperscript{a}/JK\textsuperscript{b}  |
| FY\textsuperscript{b}/FY\textsuperscript{b} | 0         | Fy(a+b+)                  | JK\textsuperscript{b}/JK\textsuperscript{b}  |

Kappa 0.368, p<0.001 for Duffy system; kappa 0.404, p<0.001 for Kidd system.

**Genotyping**

The DNA was extracted from peripheral blood leucocytes using a DNA extraction kit (GeneJet Genomic DNA Purification Kit, Thermo Fisher Scientific, USA), following the manufacturer’s instructions. Polymorphism was identified by polymerase chain reaction-restriction length polymorphism (PCR-RFLP) analysis according to Reid et al. [7]. Briefly, each PCR reaction was carried out in a total volume of 25 µL containing 1X DreamTaq standard buffer, template DNA, 50 pM of each primer, 2.0 mM MgCl\textsubscript{2}, 200 µM of each dNTP, and 1 U of DreamTaq DNA polymerase (Thermo Fisher Scientific) with annealing at 62 °C.

The amplification products were then digested overnight by restriction endonuclease Ban\textsubscript{I} (Thermo Fisher Scientific), following the manufacturer’s instructions. The fragments were separated electrophoretically using 2% agarose gel containing ethidium bromide.

The Duffy antigen is present in 2 major allelic forms, FY\textsuperscript{A} and FY\textsuperscript{B}, differing in an amino acid at position 42 (Gly42Asp) of the Duffy antigen receptor. The amino acid

| Genotype FY\textsuperscript{A}/FY\textsuperscript{B} - phenotype Fy(a+b+) | 10 | 30.3 |
| Genotype FY\textsuperscript{B}/FY\textsuperscript{B} - phenotype Fy(a+b+) | 19 | 57.6 |
| Total                                   | 29 | 87.9† |

†: statistically significant difference (z-test, p<0.05).
change occurs because of G125A polymorphism in the Duffy antigen receptor for the chemokine gene (DARC).

The Kidd antigen system is known to comprise 2 major alleles, JK*A and JK*B, which result from a single nucleotide polymorphism (838G→A) in gene SLC14A1. The corresponding JK*A and JK*B antigens differ by a single amino acid (D280N).

**Statistical Analysis**

The comparison of medians between the groups was performed by applying the nonparametric Mann-Whitney U test. We did not compare the means because the values of the studied variables were not normally distributed (Kolmogorov-Smirnov test, p<0.05). The 2-proportion z-test, chi-square test, and Fisher’s exact test (for small samples) were used for categorical data analysis. The level of agreement between dichotomous results of 2 tests was measured using Cohen’s kappa. Differences were considered significant at p<0.05. IBM SPSS Statistics 20 was used for the data analysis.

**Results**

**Donors**

Coincidence between phenotype and genotype was observed in all 49 donor samples.

**Patients**

Disagreements of phenotype and genotype between the Duffy and Kidd systems were found in one-third of the samples of 101 patients who had recently undergone transfusion. The results of phenotyping and genotyping are presented in Table 1.

To analyse the impact of time from the last transfusion on the discrepancies of the results, patients were distributed

| Table 3. Kidd phenotyping and genotyping discrepancies and time from last red blood cells transfusion. |
|---|---|---|---|
| **Time from the Last Transfusion** | **<4 Weeks** | **>4 Weeks** |
| **Results** | **n=69** | **Number** | **Percent of Total** | **n=32** | **Number** | **Percent of Total** |
| Genotype JK*A/JK*A - phenotype Jk(a+b+) | 17 | 53.1 | 3 | 9.4 |
| Genotype JK*B/JK*B -phenotype Jk(a+b+) | 10 | 31.3 | 2 | 6.2 |
| Total | 27 | 84.4† | 5 | 15.6† |

†: statistically significant difference (z-test, p<0.05).

| Table 4. Distribution of Duffy and Kidd antigens and phenotypes. |
|---|---|---|---|
| **Duffy System** | **Patients, Controls, n** | **Percent of Total** | **Literature, %** | **p-Value** |
| Fy(a+) | 105 | 70 | 66 | 0.172* |
| Fy(b+) | 124 | 82.7 | 83 | 0.5* |
| Fy(a+b+) | 79 | 52.7 | 49 | 0.207* |
| Fy(a+b-) | 26 | 17.3 | 17 | 0.5* |
| Fy(a-b+) | 45 | 30 | 34 | 0.172* |
| **Kidd System** | | | | |
| Jk(a+) | 116 | 75.3 | 77 | 0.923* |
| Jk(b+) | 105 | 70 | 74 | 1* |
| Jk(a+b+) | 71 | 47.3 | 50 | 0.568* |
| Jk(a+b-) | 45 | 30 | 24 | 0.052* |
| Jk(a-b+) | 34 | 22.7 | 26 | 0.201* |

*: Frequencies of Duffy and Kidd antigens and phenotypes were compared with literature data (nonparametric binomial test).
into 2 groups. The first group included those who received RBCs less than 4 weeks before and the second group more than 4 weeks before the sample collection. The influence of the number of transfused RBCs on the disagreement of the results was also analysed.

**Duffy System**

A total of 33 (32.7%) phenotype/genotype discrepancies were assessed. However, in samples that did not contain one of the Duffy antigens, discrepant results were found in 68.8% of cases.

Significant differences in phenotype/genotype disagreements between the 2 aforementioned groups were found in 29 and 4 cases, respectively (Table 2).

The comparison of the duration of time after the last transfusion between the 2 groups of patients with accurate and discrepant phenotype/genotype results also showed a significant difference. The median of days after the last transfusion was found to be 14 (mean: 15.52±1.95) in the group with discrepant results versus 25 (mean: 28.72±2.23) in the group with accurate results (p=0.001).

No effect of transfused RBCs per year on Duffy phenotyping and genotyping discrepancies was detected: 605 units [median: 5 (mean: 8.91±1.5, range: 3-46)] were transfused to patients with accurate phenotype/genotype results, and 294 units [median: 6 (mean: 8.91±1.4, range: 3-81)] to those with discrepant results (p=0.207).

Significantly different results were found when comparing the number of RBC units transfused during the last 3 months between the 2 aforementioned groups. A median of 5 (mean: 6.85±0.69) units were transfused during this period to the patients with discrepant phenotype/genotype results versus 4 (mean: 5.71±0.5) to those with accurate results (p=0.025).

**Kidd System**

Disagreements between genotyping and serologic typing for Jk̄/Jkb were found in 32 (31.7%) blood samples, while 4 (mean: 5.71±0.5) to those with accurate results (p=0.025). There was no difference with regard to the number of RBC units transfused during the last 3 months between the 2 aforementioned groups, either. A median of 6 (mean: 6.28±0.48) units were transfused during this period to the patients with discrepant phenotype/genotype results versus a median of 4 (mean: 5.99±0.56) to those with accurate results (p=0.71).

**Phenotype Frequencies**

Genotyping results were used to determine the expected Duffy and Kidd phenotype frequencies. No differences were found when comparing these results with those of other authors [8,9]. The phenotypes of 101 patients and 49 controls are presented in Table 4.

**Discussion**

It is still disputable which situations require extended typing of transfused RBCs beyond routine matching for ABO, RhD, and existing antibodies. Although a number of studies found that SCD or β-thalassaemia patients may benefit from extended antigen matching, there is still a lack of recommendations in this context for other patients undergoing long-term RBC transfusions [1,11,12].

Additional antibodies are known to occur in 20% to 90% of previously alloimmunised patients [13,14,15]. Schonewille et al. evaluated the incidence of new antibody formation with subsequent transfusion in 22% of alloimmunised haematology/oncology patients and in 20%-25% of the non-haematology/oncology cohort [14,15]. The transfusion of extended antigen-matched RBCs, including Duffy and Kidd systems, has been shown to lower alloimmunisation in about 70% of cases [16,17]. According to these studies as well as those investigating SCD patients, extended antigen matching could be recommended for haematology-oncology patients and other subjects who undergo long-term transfusions.

We agree with the many authors who state that antigen typing of recently transfused patients is not always accurate, as their peripheral blood contains transfused cells [5,6,13,18,19]. Several reports describe this type of discrepancy in up to 10% of cases for the Duffy and Kidd systems by comparing phenotyping and genotyping results [6,18,20]. These findings differ from our data, which showed a much higher rate of discrepancies (32.7% and 31.7%), although the results cannot be accurately compared because other authors failed to provide information about the number of transfused RBC units or the time frame from the last transfusion.

In contrast to a number of previous studies [6,18,20,21,22], our data do not suggest the presence of additional Duffy system alleles (which are known to be associated with reduced or abolished gene expression) either in patients or in
of 24 samples in our study showed positive (2+ to 4+) results particularly for the Kidd system [5,7]. In this group, a total sample collection also differed from those reported earlier, who received transfusions within a time period of 7 days before Caucasian population were tested in our study.

Our data suggest the need for blood group genotyping (including the Duffy and Kidd systems), which was proposed by many authors [1,2,3,4,5,6,7,11,13,16,18,19,20,23,24,25]. Nevertheless, one should determine when genotyping should replace serology or be combined with it for patients undergoing long-lasting RBC transfusions. This is particularly important for institutions that do not perform blood group genotyping routinely. We found in our study that Duffy genotyping/phenotyping disagreements depended on the number of transfused RBC units during the last 3 months. However, it would be difficult to predict how many units would cause these discrepancies or to make specific recommendations. The limitation of our study is the small number of subjects, which complicated their grouping according to the number of transfused RBC units.

The results of our study regarding the effect of the length of time after the last transfusion on serology findings are useful in clinical practice. A significantly lower number of Duffy and Kidd phenotyping/genotyping discrepancies was found in patients who underwent their last transfusions more than 3 (p=0.01 and p=0.017, respectively) or 4 (p=0.003 and p=0.018, respectively) weeks before the sample collection. Only one disagreement for the Duffy system (compared to 3 for the Kidd system) was found when the time from the last transfusion was from 6 to 7 weeks. No discrepancies were found for either system when the last transfusion was performed more than 7 weeks before.

Our data are also in agreement with previous reports indicating that the range of agglutination in mixed-field reactions does not predict the actual antigen typing [7]. For example, 10 patients in the discrepant group with 2+ reaction for Fya and 2+ or 3+ reaction for Fyb had FY*A/FyB/FY*B genotypes. In the group with accurate results, 7 genotypically FY*A/FY*B samples also showed 2+ agglutination with anti-Fya. An exception could be made for serologic reactions with the expression of 1+. All 5 of the 1+ reactions in the Duffy system typing as well as 8 respective reactions in the Kidd typing genetically showed no allele expression. Those reactions were classified as serologically negative. More research is needed to confirm this statement.

Conclusions

Our study showed that Duffy or Kidd phenotyping with agglutination tests is inappropriate for patients who have recently undergone blood transfusion. Genotyping should be considered when the patient underwent transfusion less than 4 weeks before the sample collection. The group of patients who recently (<7 weeks) received RBC transfusion and require genotyping in addition to phenotyping are those who are homozygous for either Duffy or Kidd, but this cannot be ascertained using serology. Agglutination tests can be reliably used for donors and patients who have been transfused more than 7 weeks before.

Furthermore, the accurate typing of both the Kidd and Duffy systems before the first transfusion could be beneficial. A significantly lower number of Duffy and Kidd phenotyping/genotyping discrepancies was found in patients who have recently received multiple transfusions. Transfusion 2012;52:381-388.

Conflict of Interest Statement

The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

References

1. Wilkinson K, Harris S, Gaur P, Haile A, Armour R, Teramura G, Delaney M. Molecular typing augments serologic testing and allows for enhanced matching of red blood cells for transfusion in patients with sickle cell disease. Transfusion 2012;52:381-388.
2. Hillyer CD, Shaz BH, Winkler AM, Reid M. Integrating molecular technologies for red blood cell typing and compatibility testing into blood centers and transfusion services. Transfus Med Rev 2008;22:117-132.
3. Ribeiro KR, Guarnieri MH, Costa DC, Costa FF, Pelegrino Jr, Castilho L. DNA array analysis for red blood cell antigens facilitates the transfusion support with antigen-matched blood in patients with sickle cell disease. Vox Sang 2009;97:147-152.
4. Chou ST, Westhoff CM. The role of molecular immunohematology in sickle cell disease. Transfus Apher Sci 2011;44:73-79.
5. Rozman P, Dovc T, Gassner C. Differentiation of autologous ABO, RHD, RHCE, KEL, JK and FY blood group genotypes by analysis of peripheral blood samples of patients who have recently received multiple transfusions. Transfusion 2000;40:936-942.
6. Guelsin GA, Sell AM, Castilho L, Masaki VL, Melo FC, Hashimoto MN, Higa TT, Hirle LS, Visentainer EL. Benefits of blood group genotyping in multi-transfused patients from the south of Brazil. J Clin Lab Anal 2010;24:311-316.
7. Reid ME, Rios M, Powell VI, Charles-Pierre D, Malavade V. DNA from blood samples can be used to genotype patients who have recently received a transfusion. Transfusion 2000;40:48-53.
8. Meny GM. The Duffy blood group system: a review. Immunohematology 2010;26:51-56.
9. Westhoff CM, Reid ME. Review: the Kell, Kidd, Duffy and Kidd blood group systems. Immunohematology 2004;20:37-49.
10. Schwickerath V, Kowalski M, Menitove JE. Regional registry of patient alloantibodies: first-year experience. Transfusion 2010;50:1465-1470.
11. Castilho L, Rios M, Pellegrino J Jr, Saad STO, Costa FF. Blood group genotyping facilitates transfusion of β-thalassemia patients. J Clin Lab Anal 2002;16:216-220.
12. Klapper E, Zhang Y, Figueroa P, Ness P, Stubbs J, Abumuhor I, Bailey J, Epperson L, Taucher C, Enrique E, Hashmi G, Seul M. Toward extended phenotype matching: a new operational paradigm for the transfusion service. Transfusion 2010;50:536-546.
13. Denomme GA, Flegel WA. Applying molecular immunohematology discoveries to standards of practice in blood banks: now is the time. Transfusion 2008;48:2461-2475.
14. Schonewille H, de Vries R, Brand A. Alloimmune response after additional red blood cell antigen challenge in immunized hematopoietic patients. Transfusion 2009;49:453-457.
15. Schonewille H, van de Watering L, Brand A. Additional red blood cell alloantibodies after blood transfusions in a nonhematologic alloimmunized patient cohort: is it time to take precautionary measures? Transfusion 2006;46:630-655.
16. Anstee DJ. Red cell genotyping and the future of pretransfusion testing. Blood 2009;114:248-256.
17. Verduzco LA, Nathan DG. Sickle cell disease and stroke. Blood 2009;114:5117-5125.
18. Castilho L, Rios M, Bianco C, Pellegrino J Jr, Alberto FL, Saad ST, Costa FF. DNA-based typing of blood groups for the management of multiply-transfused sickle cell disease patients. Transfusion 2002;42:232-238.
19. Avent ND. Large-scale blood group genotyping: clinical implications. Br J Haematol 2008;144:3-13.
20. Castilho L, Rios M, Pellegrino J Jr, Carvalho MHH, Alberto FL, Saad STO, Costa FF. Genotyping of Kell, Duffy, Kidd and RHD in patients with β-thalassemia. Transfusion 2000;22:69-76.
21. Castilho L. The value of DNA analysis for antigens in the Duffy blood group system. Transfusion 2007;47:28-31.
22. Cotorruelo C, Biondi C, Racca L, Borras SG, Racca A. Duffy genotyping facilitates transfusion therapy. Clin Exp Med 2009;9:249-251.
23. Westhoff CM. Molecular testing for transfusion medicine. Curr Opin Hematol 2006;13:471-475.
24. Castro O, Sandler SG, Houston-Yu P, Rana S. Predicting the effect of transfusion only phenotype-matched RBCs to patients with sickle cell disease: theoretical and practical implications. Transfusion 2002;42:684-690.
25. Lomas-Francis C. The value of DNA analysis for antigens of the Kidd blood group system. Transfusion 2007;47:23-26.